Participated · Equity · Mar 2026

BioCaptiva, a University of Edinburgh spin-out, has created the msX magnetic bead platform, which extracts circulating cell-free DNA directly from whole blood without centrifugation or extra reagents. By delivering higher-quality DNA with simpler, faster, and fully automatable workflows, the technology tackles a long-standing bottleneck in liquid biopsy sample preparation, a rapidly expanding segment of non-invasive cancer testing. The company recently launched msX research-use-only kits in Boston to generate supporting data across multiple oncology applications. New Chief Technology Officer Alan Schafer, who previously held senior roles at Inivata, Population Genetics Technologies, 14M Genomics, and GSK, has been hired to drive product and technology development. The fresh capital will fund continued R&D and the expansion of BioCaptiva’s product portfolio and applications. Financially, the company secured £1.58 million in its latest round, led by existing backer Archangels alongside several institutional investors, demonstrating ongoing investor confidence as BioCaptiva enters a key commercialization phase.

Participated · Series A · Jan 2026

Evaro is an NHS-licensed digital healthcare platform founded by medical professionals to embed regulated online care within consumer brands’ existing digital experiences. Its healthcare-as-a-service stack covers asynchronous consultations, remote diagnostics, prescribing, dispensing and aftercare, and can be integrated in a short timeframe with minimal engineering lift for partners. The system supports treatment across more than 80 common conditions and has already served over two million patients through various consumer-facing brands. By enabling trusted non-clinical companies to add healthcare offerings, Evaro creates new revenue streams and deeper customer engagement while helping relieve pressure on overstretched UK primary care. The company generates income from these brand partnerships, though detailed revenue figures were not disclosed. With fresh capital in hand, Evaro intends to expand its reach and further develop its infrastructure for the UK market. The new funding round signals investor confidence in the firm’s traction and its ability to scale regulated digital healthcare delivery.